Zymeworks Inc. develops and manages licensed healthcare assets while advancing a pipeline of novel, multifunctional biotherapeutics for oncology. Company news centers on Ziihera (zanidatamab-hrii) and zanidatamab-related regulatory and clinical updates, including HER2-targeted development, as well as ZW191, a folate receptor alpha-targeting antibody-drug conjugate with Fast Track designation for advanced or metastatic platinum-resistant ovarian cancer.
Recurring updates also cover antibody-drug conjugate platform work, including RAS inhibitor ADC programs and targets such as CLDN18.2, Ly6E and PTK7, along with financial results, cash resources, share repurchase activity, investor conference participation and executive leadership appointments.
Zymeworks Inc. (NYSE: ZYME) announced the completion of patient enrollment ahead of schedule in its pivotal trial (HERIZON-BTC-01) for zanidatamab, a therapy targeting HER2 in biliary tract cancers. This achievement reinforces their commitment to developing new treatments. Financially, revenue rose to $1.9 million from $0.6 million year-over-year, though net losses increased to $72.6 million. The company plans to enhance funding through collaborations while controlling expenses. Zymeworks aims to submit two new IND applications by 2024 and will present data at ASCO in June.
On May 3, 2022, All Blue Capital announced that Dr. Alan Barge, an expert in oncology and biopharmaceutical drug development, will serve as an advisor during their proposed acquisition of Zymeworks (NYSE: ZYME). All Blue has proposed acquiring Zymeworks for $10.50 per share, totaling approximately $773 million in equity value. The aim is to reverse Zymeworks' recent underperformance and enhance operational performance. Dr. Barge's extensive background, including his experience at AstraZeneca, is expected to contribute significantly to Zymeworks’ turnaround.
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company, will participate in the H.C. Wainwright Global Investment Conference from May 24-26. They will hold virtual one-on-one meetings and a corporate presentation on May 24 at 7 a.m. ET. This presentation will be accessible via Zymeworks’ website. Zymeworks focuses on developing next-generation multifunctional biotherapeutics, with lead candidate zanidatamab currently in multiple trials for solid tumors expressing HER2. For more details, visit their corporate site.
Zymeworks Inc. (NYSE: ZYME) has received an unsolicited, non-binding proposal from All Blue Falcons FZE (ABF) to acquire the company for $10.50 per share in cash. The Zymeworks board will review this proposal carefully to determine the best course of action for the company and its shareholders. No formal offer has been made yet, and shareholders do not need to take any action at this time. Zymeworks focuses on developing multifunctional biotherapeutics, including its leading clinical candidates, zanidatamab and ZW49.
Zymeworks Inc. (NYSE: ZYME) has completed enrollment in its pivotal HERIZON-BTC-01 clinical trial, assessing the antitumor efficacy of zanidatamab for patients with advanced HER2-amplified biliary tract cancers. Results are anticipated in early 2023. This trial addresses a significant need, as over 210,000 new cases of biliary tract cancers are diagnosed globally each year, with limited treatment options available. Zanidatamab has received Breakthrough Therapy designation from the FDA for this indication, highlighting its potential to improve patient outcomes.
Zymeworks Inc. (NYSE: ZYME) announced the acceptance of two abstracts for poster presentations at the 2022 ASCO Annual Meeting, scheduled for June 3-7, 2022. The first poster will showcase Phase 1b/2 data of zanidatamab combined with CAPOX chemotherapy and tislelizumab for HER2-positive advanced gastric cancer on June 4. The second presentation, on June 6, will feature preliminary data of zanidatamab with docetaxel for advanced HER2-positive breast cancer. Both presentations will be accessible on the Zymeworks website.
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company, will announce its Q1 2022 financial results on May 4, 2022, after market close. A conference call and webcast to discuss the results will follow at 4:30 p.m. ET. Investors can join the call by dialing 844-435-7258 (U.S. & Canada) or +1-631-485-4286 (international). Zymeworks is known for its innovative biotherapeutics, including its lead candidate, zanidatamab, a HER2-targeted bispecific antibody currently in clinical trials.
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical firm, announced its participation in two key investor conferences. On April 12, the company will hold one-on-one meetings at the Wells Fargo 2022 Biotech Forum in Palm Beach Gardens, FL. Additionally, Zymeworks will present and participate in meetings on May 2 at Bloom Burton & Co. Healthcare Investor Conference at 2:00 p.m. ET. These events will be webcast live, providing further engagement opportunities for investors.
Zymeworks Inc. (NYSE: ZYME) announced participation in two upcoming investor conferences in March 2022. The company will present at the Barclays Global Healthcare Conference on March 16 at 8:00 a.m. ET in Miami, FL, and a virtual fireside chat at Citi’s 2022 Winter Biotech Virtual Bus Tour on March 23 at 2:45 p.m. ET. Both events will be available via live webcast on Zymeworks’ website. Zymeworks is focused on developing next-generation biotherapeutics, including its lead candidate, zanidatamab, for treating solid tumors expressing HER2.
Zymeworks Inc. (NYSE: ZYME) reports pivotal trial progress for zanidatamab in gastroesophageal adenocarcinoma and biliary tract cancer, with expected enrollment completion dates in 2023 and mid-2022, respectively. The company's financial position is enhanced by a successful equity offering in January 2022, extending its cash runway into the second half of 2023. A workforce reduction exceeding 25% is in progress, alongside the appointment of Chris Astle, PhD, as CFO. Zymeworks expects to provide significant data updates in 2022 and continues to focus on partnerships to strengthen its financial position.